Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mannitol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | TOP1 | P11387 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mannitol SCHEMBL21327681 | 1.00 | LMNA (0.73) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL1605233 | 1.00 | LMNA (0.73) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Adonitol SCHEMBL27608468 | 0.93 | TDP1 (0.67) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Xylitol SCHEMBL18429950 | 0.93 | TDP1 (0.67) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL3936883 | 0.91 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL28076153 | 0.91 | LMNA (0.61) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL9456465 | 0.90 | LMNA (0.79) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL26129004 | 0.87 | LMNA (0.55) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL6244361 | 0.86 | LMNA (0.85) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL28032309 | 0.86 | LMNA (0.85) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363610-A1 | ENZYME FORMULATIONS AND REACTION MIXTURES FOR NUCLEIC ACID AMPLIFICATION | Gen-Probe Incorporated (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023278529-A1 | ENZYME FORMULATIONS AND REACTION MIXTURES FOR NUCLEIC ACID AMPLIFICATION | GEN-PROBE INCORPORATED (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-3698637-A1 | SOFT, 3D-SHAPED, SEMI-RIGID TORTILLAS | General Mills, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10660944-B2 | Stable formulations for CNS delivery of arylsulfatase A | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190125841-A1 | STABLE FORMULATIONS FOR CNS DELIVERY OF ARYLSULFATASE A | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-1782696-B1 | Method for manufacturing human food applications or intermediates for non-food applications and human food application or intermediate for non-food application | TEREOS STARCH & SWEETENERS BELGIUM (BE) | 2019-01-23 | — | — | EP | disclosed |
| CN-102395379-B | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor | TEVA BIOPHARMACEUTICALS USA INC | 2015-07-22 | — | — | CN | disclosed |
| CN-102395379-A | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor | TEVA BIOPHARMACEUTICALS USA INC | 2012-03-28 | — | — | CN | disclosed |
| CN-101249095-B | Preparation of emulsifiable paste for containing decoloring agent, tretinoin and skinniness steroids | CHONGQING PHARM RES INST CO | 2011-08-31 | — | — | CN | disclosed |
| CN-101249095-A | Preparation of emulsifiable paste for containing decoloring agent, tretinoin and skinniness steroids | CHONGQING PHARM RES INST CO (CN) | 2008-08-27 | — | — | CN | disclosed |
| EP-1942913-A1 | USE OF NOT EASILY WATER-SOLUBLE CALCIUM SALTS AND/OR THE COMPOSITES THEREOF | Sus Tech GmbH & Co. KG (DE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007051546-A1 | USE OF NOT EASILY WATER-SOLUBLE CALCIUM SALTS AND/OR THE COMPOSITES THEREOF | SUS TECH GMBH & CO. KG (DE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070093507-A1 | Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives | LAMBROU GEORGE N | 2007-04-26 | — | — | US | disclosed |
| US-5889020-A | REDUCING EYE PRESSURE | CIBA VISION CORPORATION (US) | 1999-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125841-A1 | STABLE FORMULATIONS FOR CNS DELIVERY OF ARYLSULFATASE A | ARSA, GBA2, ASAH2 | LMNA 2881/4885L3MBTL1 2007/4885TDP1 2782/4885 |
| US-10660944-B2 | Stable formulations for CNS delivery of arylsulfatase A | ARSA, GBA2, ASAH2 | LMNA 2881/4885L3MBTL1 2007/4885TDP1 2782/4885 |
| US-20070093507-A1 | Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives | PTGIS, PTGES, PTGS2 | LMNA 1160/4885L3MBTL1 4855/4885TDP1 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.